Form 4 holding
Director
IMARA Inc.
- Security class
- Common Stock
- Shares / value
- 2,344,072
- Estimated value
- $35,477,530
- Report date
- 02 Jun 2022
- Price
- $15.14
- Ownership
- By entities affiliated with Arix Bioscience plc
Mark Chin - Director at Enliven Therapeutics, Inc.
Issuer-level insider activity
- Role
- Director
- Issuer ticker
- ELVN on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Mark Chin since 13 Sep 2025
Reported holdings for Mark Chin in Enliven Therapeutics, Inc.
Form 4 holding
Director
IMARA Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 8,500
- Estimated value
- Report date
- 02 Jun 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Mark Chin in Enliven Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.